FDA recall, , Moderate risk
New York Blood Center Enterprises Apheresis Platelets, Leukocytes Reduced, Irradiated
Apheresis Platelets, Leukocytes Reduced, Irradiated tested repeatedly reactive for anti-HCV and were distributed.
New York Blood Center Enterprises began this recall on Nov 10, 2025. FDA posted it on Nov 3, 2026, the day the recall ended.
Summary by Recall Canary from the FDA notice
What happened
New York Blood Center Enterprises, located in Rye, New York, voluntarily initiated a recall of Apheresis Platelets, Leukocytes Reduced, Irradiated because the product tested repeatedly reactive for anti-HCV and was distributed. The recall began on November 10, 2025, and was added to the FDA's Enforcement Report and classified by the FDA on November 3, 2026. Customers were notified by fax, and the distribution occurred in New York.
What to do
Biologics such as blood, tissue and vaccines are usually given by hospitals and clinics. If you had a transfusion, transplant, infusion or vaccine, ask the place that treated you whether this product was used. If they contact you, follow their advice.
What was recalled
Hospitals, clinics and blood banks match these details against their records.
Apheresis Platelets, Leukocytes Reduced, Irradiated
- Unit number
- W047025005488
Recall details
- Posted by FDA
- Recall began
- Status
- Ended Nov 3, 2026
- Weekly archive
- Listed the week of Nov 2, 2026
- Distributed to
- Recalled by
- New York Blood Center EnterprisesRye, New York
- Hazard
- Donor screening problem
- Risk
Moderate risk
Its use may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- FDA event number
- 100256
- Recall number
- B-0035-2027
- Recall type
- Voluntary: Firm initiated
- How the company first told customers
- FAX
All recalls from New York Blood Center Enterprises
Timeline
FDA's Enforcement Report is its public list of recalls; FDA posts a recall by adding it there.
New York Blood Center Enterprises began the recall
FDA posted the recall to its Enforcement Report, rated it Class II (moderate risk) and closed it
Added to Recall Canary